AI Article Synopsis

  • The study assessed Wenxin Granules for treating arrhythmias related to Qi and Yin deficiency, using multi-criteria decision analysis to evaluate safety, effectiveness, economy, innovation, and accessibility.
  • Wenxin Granules were found to have a controllable safety risk (grade B) primarily concerning gastrointestinal damage, while their effectiveness was rated grade A, showing better clinical results than conventional antiarrhythmic medications.
  • Economically, Wenxin Granules are more cost-effective (grade B) and exhibit a clear innovation in clinical applications, with an overall accessibility rating influenced by minimal restrictions and sustainable resource availability.

Article Abstract

This study evaluated the safety, effectiveness, economy, innovation, suitability, accessibility, and characteristics of traditional Chinese medicine of Wenxin Granules in the treatment of arrhythmia(ventricular premature beat and atrial premature beat) with deficiency of Qi and Yin. The multi-criteria decision analysis(MCDA) model was adopted, and the criterion layer and index layer were weighted by experts. CSC v2.0 was used for clinical comprehensive evaluation. This study embodies the clinical value of Wenxin Granules, promotes its safe, effective and rational use, and provides a basis for national medical decision-making. The multi-source evidence shows that the major adverse reaction of Wenxin Granules is gastrointestinal damage. According to the available studies, Wenxin Granules has controllable risk and thus is rated as grade B in terms of safety. The systematic evaluation of effectiveness shows that compared with antiarrhythmic western medicine, Wenxin Granules demonstrates improved clinical efficacy and electrocardiogram efficacy, which is supported by high-quality evidence, and thus the effectiveness of Wenxin Granules is evaluated as grade A. Economic research shows that Wenxin Granules is more economical than antiarrhythmic western medicine, which is supported by sufficient evidence and clear results, and thus the economy of this preparation is rated as grade B. The indications and contraindications of Wenxin Granules are clear and detailed to different types of arrhythmia, which, together with the precise positioning and prominent clinical innovation and industrial innovation, rates it as grade A in terms of innovation. The suitability of drug storage, prescription circulation, dosage form and course of treatment basically meet the clinical medication needs of doctors and patients, and thus the suitability of Wenxin Granules is evaluated as grade B. Because of the few restrictions and the sustainable resources of medicinal materials, the accessibility of Wenxin Granules is evaluated as grade A. The prescription compatibility focuses on the pathogenesis characteristics of deficiency of Qi and Yin, and there are more than 3 000 cases studied. Therefore, the characteristics of traditional Chinese medicine of Wenxin Granules are evaluated as grade B. Based on the evidence from all the above dimensions, Wenxin Granules has the clinical comprehensive value of class A and prominent characteristics of traditional Chinese medicine. It is suggested to include Wenxin Granules into the policy results related to basic clinical medication management according to the procedure.

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20210930.503DOI Listing

Publication Analysis

Top Keywords

wenxin granules
56
granules evaluated
16
evaluated grade
16
wenxin
14
granules
14
characteristics traditional
12
traditional chinese
12
chinese medicine
12
medicine wenxin
12
comprehensive evaluation
8

Similar Publications

Background: Chinese patent medicines (CPMs) are widely used in China as an adjuvant treatment in dilated cardiomyopathy with heart failure (DCM-HF). However, comprehensive and systematic evidence supporting the beneficial effects of CPMs combined with current complementary and alternative medicine (CAM) treatments against DCM-HF was limited. This network meta-analysis (NMA) aimed to assess and rank the relative efficacy of eight different CPMs for DCM-HF.

View Article and Find Full Text PDF
Article Synopsis
  • A network meta-analysis was conducted to evaluate the effectiveness and safety of various Chinese patent medicines for treating chronic pulmonary heart disease, analyzing data from numerous databases including CNKI, PubMed, and Cochrane Library, up to December 2023.
  • The analysis included 95 randomized controlled trials (RCTs) with a total of 8,787 patients and assessed multiple Chinese patent medicines, focusing on metrics like cardiac function, forced expiratory volume, and partial pressure of gases in the blood.
  • Top-performing treatments combined Chinese medicines with conventional western medicines, including Wenxin Granules, Tongxinluo Capsules, and Qishen Yiqi Dropping Pills for overall efficacy and improvements in respiratory function.
View Article and Find Full Text PDF

This study employed evidence mapping to systematically sort out the clinical studies about the treatment of premature ventricular contractions with Chinese patent medicines and to reveal the distribution of evidence in this field. The articles about the treatment of premature ventricular contractions with Chinese patent medicines were searched against PubMed, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP with the time interval from January 2016 to December 2022. Evidence was analyzed and presented by charts and graphs combined with text.

View Article and Find Full Text PDF

Bayesian network Meta-analysis was performed to evaluate the efficacy and safety of different Chinese patent medicines in the treatment of dilated cardiomyopathy. The PubMed, EMbase, Cochrane Library, CNKI, Wanfang, and VIP were searched for the randomized controlled trial(RCT) from the inception to May 2023. The quality of the included RCT was evaluated by the Cochrane risk of bias assessment tool, and the data were analyzed by RStudio 3.

View Article and Find Full Text PDF

Salmonella should be absent in pharmaceutical preparations and foods according to the regulations. However, up to now, rapid and convenient identification of Salmonella is still full of challenge. Herein, we reported a label-free surface-enhanced Raman scattering (SERS) method for direct identification of Salmonella spiked in drug samples based on a characteristic bacterial SERS marker assisted by a high-performance SERS chip and a selective culture medium.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!